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Abstract Laboratories and laboratory networks are a fundamental component of tuberculosis (TB) control, providing testing for 
diagnosis, surveillance and treatment monitoring at every level of the health-care system. New initiatives and resources to strengthen 
laboratory capacity and implement rapid and new diagnostic tests for TB will require recognition that laboratories are systems that 
require quality standards, appropriate human resources, and attention to safety in addition to supplies and equipment. To prepare 
the laboratory networks for new diagnostics and expanded capacity, we need to focus efforts on strengthening quality management 
systems (QMS) through additional resources for external quality assessment programmes for microscopy, culture, drug susceptibility 
testing (DST) and molecular diagnostics. QMS should also promote development of accreditation programmes to ensure adherence to 
standards to improve both the quality and credibility of the laboratory system within TB programmes. Corresponding attention must be 
given to addressing human resources at every level of the laboratory, with special consideration being given to new programmes for 
laboratory management and leadership skills. Strengthening laboratory networks will also involve setting up partnerships between TB 
programmes and those seeking to control other diseases in order to pool resources and to promote advocacy for quality standards, to 
develop strategies to integrate laboratories’ functions and to extend control programme activities to the private sector. Improving the 
laboratory system will assure that increased resources, in the form of supplies, equipment and facilities, will be invested in networks 
that are capable of providing effective testing to meet the goals of the Global Plan to Stop TB.
Bulletin of the World Health Organization 2007;85:354-359.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Introduction
The laboratory has always played a criti-
cal role in diagnosing tuberculosis (TB) 
and monitoring its treatment. In the new 
millennium, the strength of the labora-
tory network is often a direct reflection 
of the success of TB control programmes. 
Developed countries have taken advan-
tage of new technologies that provide 
rapid detection, identification and drug 
susceptibility testing of Mycobacterium 
tuberculosis, hastening the decline of the 
prevalence of the disease1–3 when com-
bined with good treatment programmes. 
In contrast, many developing countries 
are burdened with high rates of TB 
and struggle to provide good-quality 
microscopy, with access to culture and 
drug susceptibility testing (DST) being 
scarce to non-existent. For a long time, 
countries have demonstrated effective 
TB control using microscopy-based di-
agnosis and monitoring combined with 
well-managed treatment programmes. 
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However, inadequate management and 
support of TB programmes and the labo-
ratory networks are hindering progress 
against the disease. Also, the complica-
tions stemming from the HIV epidemic 
and multidrug-resistant TB (MDR-TB), 
especially in Africa and eastern Europe, 
prevent effective TB control that relies 
entirely on microscopy-based case detec-
tion and management. Effective control 
involves access to laboratory services at 
every level, which requires managing 
and supporting laboratory networks 
that provide reliable and consistent de-
centralized services. Although labora-
tory strengthening is beginning to gain 
higher priority on the TB agenda, as 
reflected in the new Stop TB Strategy, 
more efforts are needed to improve access 
to and utilization of existing diagnostics 
as well as to develop and implement new 
technologies.4,5
Modern techniques such as fluores-
cence microscopy (FM), use of liquid 
cultures for isolation and DST, and 
amplification for detection of and/or 
for study of drug resistance are expen-
sive, labour-intensive or relatively slow. 
Increased interest has therefore emerged 
in developing new diagnostics and in 
efforts to introduce modern diagnostic 
methods in developing countries. The 
Foundation for Innovative New Diag-
nostics (FIND) is now applying a sys-
tematic approach to research and devel-
opment for new diagnostics.6 Focusing 
solely on finance, techniques and new 
diagnostics, however, often ignores the 
need for well-trained staff, quality man-
agement systems and other prerequisites 
that underpin the standards of practice 
in developed countries. Clinicians will 
continue to forgo existing laboratory 
testing services and diagnose and treat 
empirically in situations where there is 
a lack of trust and credibility concerning 
the quality of laboratory results.7 Such 
failures to have adequate quality stan-
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dards highlight the urgent need to focus 
also on strengthening the laboratory 
system in parallel with efforts to imple-
ment new techniques and methods. The 
problems of MDR-TB and the recent 
outbreaks of extensively drug-resistant 
TB (XDR-TB) provide a compelling ra-
tionale for increasing capacity for culture 
and DST services.8 In turn, the complex-
ity of providing such services is driving 
discussion and analysis of how to build 
laboratory capacity that far exceeds the 
training, human resources and networks 
required for microscopy centres. For 
countries where TB laboratory services 
are integrated with general laboratory 
services or where there is a large private 
sector, there is also a question of whether 
national tuberculosis programmes 
can successfully improve the quality 
of and access to laboratory services in 
the absence of combined efforts by all 
health programmes to support a general 
initiative of laboratory capacity-build-
ing. Past efforts to provide a separate 
and parallel system of TB microscopy 
practices, records and monitoring may 
be insufficient to meet the demands 
of improving TB laboratory services in 
the context of changing health systems.9 
There is growing recognition that the 
quality of TB laboratory networks serves 
as either the catalyst or rate-limiting step 
for further progress in TB control. This 
paper outlines some of the key technical 
and organizational challenges associated 
with microscopy, culture, DST and the 
corresponding safety issues. The differ-
ent components of successful laboratory 
services will also be examined, concentrat-
ing on human resources, research, qual-
ity management systems and laboratory 
network structure.
Microscopy
Microscopy remains the mainstay of 
rapid TB case detection, especially for 
those patients who are most infectious to 
others, with the bacterial load involved 
often reflecting the extent of disease 
requiring immediate treatment. In most 
countries, especially those with the 
highest burden of TB, the direct Ziehl– 
Neelsen (ZN) smear is still the most 
common test. However, its sensitivity 
depends on the diligence of the tech-
nician and on use of the appropriate 
technique. The co-epidemics of HIV 
infection and TB, especially in Africa, 
and concerns that the ZN smear has 
lower sensitivity in those with HIV 
infection, have stimulated interest in 
practical methods to improve micros-
copy.10,11 Industrialized countries often 
use concentrated smears and FM, a 
combination showing high yield also in 
low-income, HIV high-prevalence coun-
tries, but requiring greater resources.12 
Further operational research to demon-
strate the effectiveness and acceptance of 
this diagnostic combination under field 
conditions is required before it can be 
widely recommended.13–15 Also, external 
quality assessment (EQA) programmes 
are needed to ensure that smears are 
performed and interpreted correctly 
and that all microscopy centres achieve 
an accepted level of performance.16 Ef-
fective EQA programmes are, however, 
labour-intensive and complex, requiring 
dedicated staff for onsite supervisory visits 
and to recheck results for a relatively large 
workload of smears.17,18 Although interna-
tional guidelines recommend rechecking 
a blinded random sample of smears, many 
regions and countries have either not fully 
implemented rechecking or still use un-
blinded rechecking, the results of which 
are ineffective and misleading.19,20 The 
implementation of EQA for microscopy 
has the advantage not only of strengthen-
ing laboratory networks but of improving 
diagnostic quality.21 Systematic review by 
a laboratory expert is probably the most 
important component of strengthen-
ing network management, but is often 
limited by the cost and time involved. In 
integrated health systems, one solution 
is to broaden the scope of onsite supervi-
sion to include review and monitoring 
of other testing and diagnostic services, 
such as those for HIV, malaria, biological 
chemistry and haematology. Although 
such an integrated review would provide 
less attention for TB, it is a more efficient 
and cost-effective use of human resources, 
and reflects the common practice for 
laboratory accreditation in many high-
resource countries.
Culture methods and drug 
sensitivity testing
The use of culture methods for TB 
diagnosis and of DST are standard prac-
tices in high- resource countries; how-
ever, many low-resource countries still 
struggle to provide culture methods for 
priority needs such as drug resistance 
surveillance (DRS), extrapulmonary and 
childhood TB, and MDR-TB. There is 
considerable debate about the feasibility 
and cost of providing culture for routine 
detection of TB cases in the high-preva-
lence setting, not to mention what is the 
most appropriate diagnostic algorithm 
to use.22 However, many high-burden 
countries have not even developed the 
basic capacity for accurate and reliable 
culture for DRS and diagnosis of MDR-
TB, as shown by the lack of data on drug 
resistance in most of the high-burden 
countries.23 Additionally, national TB 
programmes need to promote appro-
priate use of the current limited culture 
capacity so that priority requests are met 
and TB laboratory services are made 
available throughout the country, and 
not just in selected urban areas.24 Recent 
outbreaks of XDR-TB have helped to 
focus attention on the selection of DST 
for diagnosis as well as for surveillance. 
The use of direct specimen testing for 
rifampin resistance using nucleic acid 
amplification tests (NAAT) avoids the 
difficulty in providing rapid, compre-
hensive and accurate DST for diagnosis 
using culture methods. NAAT also offers 
the promise of centralizing testing ser-
vices without the “cold chain” transport 
systems required for culture.25 However, 
further improvements in the sensitivity, 
cost and robustness of NAAT must 
be achieved before it can be generally 
adopted by most laboratories.26 For ex-
ample, cross-contamination of cultures 
can easily lead to false positives.27,28 Also, 
DST and NAAT require training, EQA 
and standard practices to achieve the 
levels of accuracy required to establish 
credibility and to justify the resources 
needed to further expand services.
Human resources
Management of microscopy networks 
and referral laboratories for culture and 
DST require highly skilled laboratory 
scientists, who are either in low supply 
or often unwilling to work in low-paid 
government jobs. For many countries 
the human resources crisis is limiting 
laboratory services at all levels. At the 
peripheral level, the shortage of labora-
tory technicians is forcing countries to 
train a new cadre of individuals with 
little or no formal education. For acid-
fast bacilli (AFB) microscopy and HIV 
rapid tests, these individuals who have 
been trained “on the job” can perform as 
well as formally trained laboratory tech-
nicians, but the training programmes 
must be well thought out and supported 
at all levels, and need routine EQA to 
monitor performance.18,29 The formal 
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training for laboratory technicians (or 
technologists) may vary by country, 
ranging from a 2- to 3-year diploma to 
a university degree. With the increased 
focus on skills for culture methods and 
DST, more attention will need to be 
given to the curriculum and require-
ments of laboratory technology to as-
sure that graduates have the competen-
cies required for increasingly specialized 
work. Perhaps one of the most glaring 
human resource deficiencies is the lack 
of programmes for laboratory managers 
and leaders. Whereas in many high- 
resource countries doctorates are re-
quired to direct a laboratory, in many 
African countries it is difficult to find 
laboratory staff at the national level who 
possess a graduate degree. Additionally, 
many doctorates focus on research, with 
little or no training in laboratory man-
agement and, unlike medical degrees, 
are associated with no clear career path. 
Laboratory management and network 
management are underestimated capaci-
ties that will require new mentoring and 
training activities in order to provide the 
next generation of leaders to implement 
new technologies and programmes.
Laboratory network 
structure
The challenge to developing effective labo-
ratory networks must take into account 
the evolving structure of the health-care 
system. Most high-resource countries have 
large private health-care systems, including 
laboratories, which provide high-quality 
care and services. Although the quality 
of care correlates with resources, factors 
such as laboratory quality standards and 
regulations, mandatory reporting of cases 
of TB and other infectious diseases, and 
specific public initiatives to work with 
private providers have also been responsible 
for successful integration of disease control 
programmes with private health care.30,31 
However, in many countries with a high 
burden of TB, there is a struggle to moni-
tor and assure the quality of testing and 
reporting in the growing private labora-
tory sector. In such settings, the national 
TB programmes and national reference 
laboratories (NRLs) must develop strate-
gies to enrol private laboratories in EQA 
programmes and require reporting and 
referral of TB cases. However, it is un-
likely that these bodies alone will be able 
to secure both national legislation and the 
resources to establish programmes that 
only monitor TB testing in private labo-
ratories. This will probably require efforts 
to establish partnerships with other health 
programmes to lobby for national labora-
tory standards and sufficient structure to 
implement regulations.
A key issue is the organization of the 
TB laboratory services in relation to the 
national TB programme and the general 
health services. The traditional model 
is to have the NRL located within the 
national programme. An advantage of 
this arrangement results from the close 
cooperation between the two, which 
assures that the laboratory activities are 
closely aligned with the needs of the 
programme and receive appropriate 
support. The disadvantage of having a 
“stand-alone” TB NRL versus a TB sec-
tion in an NRL facility with integrated 
laboratory services is that it can result 
in a rather small national TB laboratory 
with limited staff and service support. 
A larger integrated NRL offers many 
smaller countries the opportunity to 
share services such as support staff, 
equipment and supplies, and provides a 
greater critical mass of laboratory peers 
who can share technical expertise. An 
integrated NRL may also benefit from 
sharing quality assurance, information 
technology and specimen transporta-
tion functions. The choice may be 
even more pressing at the intermediate 
level. For individual programmes, many 
countries cannot raise the human and 
other resources required for quality 
assurance and other tasks at this level. 
The concern associated with having a 
TB section within an integrated NRL 
is to assure that the laboratory activities 
and support are closely aligned with the 
national programme. Furthermore, the 
laboratory requirements may be so much 
higher than those of the general services 
or other programmes that integration 
will be difficult. Representatives from all 
sectors of the health-care system should 
look strategically at what is the best 
structure for expanding and improving 
laboratory services.32
Laboratory safety
Safety is a continuing concern for labo-
ratory staff at all levels who work with 
specimens and cultures containing M. 
tuberculosis. It is the responsibility of the 
NRL and the national TB programme to 
address such concerns through a combi-
nation of training and education to help 
promote risk assessment and safe prac-
tices, and also to support reasonable safety 
improvements with respect to equipment, 
supplies and facilities. Microscopy carries 
a low risk if direct smears are prepared 
carefully in well-ventilated areas.33 Rather 
than purchase biological safety cabinets 
that are difficult to maintain, microscopy 
centres should invest in simple cabinets or 
“fan boxes” that are relatively inexpensive 
and efficiently exhaust air without filters, 
provided that they have sufficient extrac-
tion power.34 When suitably installed, 
such cabinets can offer a level of protec-
tion that reassures technical staff. The 
process of culture, identification and 
DST has well-defined risks of causing 
laboratory-acquired infections. These 
risks present a challenge to countries in 
terms of supporting appropriate facility 
design and engineering, training and 
adherence to safety practices, and use and 
maintenance of biological safety cabinets. 
As countries expand their culture capac-
ity, there will be a need for guidance and 
decisions on minimum safety standards 
that are affordable and sustainable.
Quality systems
The quality of testing services for TB 
remains a major barrier for microscopy, 
culture, DST and newer NAAT methods. 
Many countries are still struggling to 
expand effective EQA to all microscopy 
centres, both public and private. Effec-
tive EQA is even more important in the 
presence of HIV infection, with concerns 
that many patients will have paucibacil-
lary specimens requiring detection of 
only a few AFB to make the diagnosis 
of TB. In the meantime, EQA may 
be the most practical approach to im-
mediately improve test sensitivity, while 
further evidence is being obtained on 
the appropriateness of methods such as 
FM and concentration techniques, and 
new diagnostics are tested.35 EQA is one 
component of quality and there are proven 
programmes for measuring performance 
of microscopy and DST.36 One of the 
most effective is mentorship of NRLs 
by supranational reference laboratories 
and exchange of strains between them in 
order to measure performance in support 
of global drug resistance surveillance. 
Culture performance is often harder to 
measure, and existing EQA programmes 
do not necessarily estimate sensitivity in 
this respect. The low efficiency of culture 
methods in some settings is illustrated by 
surveillance for drug resistance, where 
some laboratories may have difficulties in 
isolating M. tuberculosis from smear-posi-
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tive specimens. These quality problems 
cannot be solved only by EQA and must 
be dealt with by total quality management 
systems that include all the components 
involved: documents, records, personnel, 
standards, facilities and quality control. 
In this respect, one critical difference in 
many developed countries is the presence 
of laboratory regulations or accreditation 
programmes.37 Until countries develop, 
implement and monitor laboratory stan-
dards by regulation, a minimum step is 
to develop an accreditation process for 
NRLs.
Research
TB laboratories also play a pivotal role in 
performing research, especially opera-
tional research that supports evidence-
based decisions for guiding labora-
tory practice. Whenever possible, such 
research should be performed in the 
field in low-resource settings, where the 
conditions represent the situation in 
most countries with a high burden of 
TB. In contrast, research performed in 
academic centres that have human and 
material resources that differ from those 
in public-sector services in low-resource 
countries may not always provide repro-
ducible results under programme condi-
tions. Research carried out to improve 
diagnostic methods and techniques can 
be published in the literature and guide 
countries’ decisions about implementing 
changes in technology and procedures. 
Many NRLs have the interest in and the 
capacity to perform operational research, 
and can be encouraged to carry it out 
if provided with training in research 
methods and by developing partnerships 
with research-focused institutions such 
as universities. It is important, how-
ever, to ensure that the NRL and other 
institutions balance research activities 
with priority initiatives to monitor and 
support the laboratory network. Finan-
cial and other incentives that are only 
available for research activities lead to 
misplaced priorities and neglect of the 
daily support that laboratory networks 
provide for TB control.
Conclusion
Laboratories are not just technologies, 
equipment and buildings; they are peo-
ple and systems that manage the pro-
cesses and standards required to produce 
accurate and timely results. Successful 
implementation of new diagnostic tests 
will still require functional networks of 
laboratories with trained and motivated 
staff, quality management systems and 
safe working environments. The Global 
Plan to Stop TB calls for 800 new cul-
ture and DST facilities at an estimated 
cost of US$ 700 million to reach its 
2015 targets.38 The Global Fund to Fight 
AIDS, Tuberculosis and Malaria can help 
with these costs; however, there will also 
have to be a corresponding requirement 
for attention and investment in people, 
organizations and systems to successfully 
expand services. Resources for commodi-
ties are increasing; nevertheless, currently 
neither funds nor efforts are directed 
towards addressing the human resources 
needed for EQA, guidance and processes 
to establish and enforce quality systems, 
practical and reasonable safety standards 
and steps to determine optimum orga-
nizational structures and requirements 
for TB laboratory services. Rather than 
assuming that technological develop-
ments are the only way to improve TB 
diagnosis, international organizations 
and countries should work immediately 
to strengthen laboratory leadership and 
systems through shared guidance at the 
global level. The solutions, in the form 
of technical guidance, effective quality 
assurance, systems and capacity build-
ing are all-attainable, but will require a 
new focus on the laboratory as a system. 
Also needed is coordination and sup-
port from organizations and countries 
in the Stop TB Partnership to develop 
the people and networks in tandem with 
improvements in facilities, equipment 
and methods. A new focus on expanding 
and strengthening laboratory systems 
for quality-assured services, that is mi-
croscopy, culture methods and DST, 
will help achieve the targets for global 
TB control.  O
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Résumé
Rôles des laboratoires et des réseaux de laboratoires dans l’efficacité des programmes de lutte 
antituberculeuse
Les laboratoires et les réseaux de laboratoire constituent une 
composante fondamentale de la lutte contre la tuberculose 
(TB), dans la mesure où ils assurent les tests diagnostiques, 
la surveillance et le suivi des traitements à tous les niveaux du 
système de soins de santé. Les initiatives et les moyens nouveaux 
destinés à renforcer la capacité des laboratoires et à mettre 
en place des tests diagnostiques innovants et rapides pour 
détecter la TB devront tenir compte de la nécessité, pour ces 
établissements, de disposer de normes de qualité et de ressources 
humaines appropriées, et aussi accorder une grande attention, 
non seulement aux fournitures et aux équipements, mais 
également à la sécurité. Pour préparer les réseaux de laboratoires 
à l’introduction de nouveaux outils diagnostiques et à une 
augmentation de leur capacité, il faut axer nos efforts sur le 
renforcement des systèmes de gestion de la qualité (SGQ) à 
travers l’apport de moyens supplémentaires aux programmes 
externes chargés d’évaluer la qualité des examens microscopiques, 
des cultures d’échantillons, des tests de pharmacosensibilité 
(DST) et des outils de diagnostic moléculaire. Les SGQ doivent 
aussi promouvoir le développement de programmes d’agrément, 
visant à garantir le respect des normes et à améliorer la qualité du 
travail et la crédibilité des réseaux de laboratoires participant aux 
programmes de lutte antituberculeuse. Il faut aussi veiller à prendre 
dûment en compte les ressources humaines à tous les niveaux des 
laboratoires et accorder une attention particulière aux nouveaux 
programmes destinés à améliorer l’administration des laboratoires 
et les compétences en matière d’encadrement. Le renforcement 
des réseaux de laboratoires supposera aussi de mettre en place des 
partenariats entre les programmes de lutte antituberculeuse et avec 
les entités s’efforçant d’endiguer d’autres maladies, afin de mettre 
en commun certaines ressources et de promouvoir l’application 
des normes de qualité, de développer des stratégies pour intégrer 
les fonctions des laboratoires et pour étendre les activités des 
programmes de lutte anti-TB au secteur privé. L’amélioration des 
réseaux de laboratoires permettra de garantir que les ressources 
supplémentaires fournies, sous forme de fournitures, de matériel 
ou d’installations, seront investies dans des réseaux en mesure 
d’effectuer des tests efficaces contribuant à la réalisation des 
objectifs du Plan mondial halte à la tuberculose.
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Los laboratorios y las redes de laboratorios son un componente 
fundamental de la lucha antituberculosa, pues realizan las 
pruebas de diagnóstico, vigilancia y monitoreo del tratamiento en 
todos los niveles del sistema asistencial. Los nuevos recursos e 
iniciativas requeridos para fortalecer la capacidad de laboratorio 
e implementar nuevas pruebas diagnósticas rápidas para la 
tuberculosis sólo serán posibles si se admite que los laboratorios 
son sistemas que requieren normas de calidad, recursos humanos 
apropiados y atención a los aspectos de la seguridad, además de 
suministros y equipo. A fin de preparar las redes de laboratorio 
para albergar nuevos medios de diagnóstico y una mayor 
capacidad, debemos centrar los esfuerzos en fortalecar los sistemas 
de gestión de la calidad invirtiendo más recursos en los programas 
de evaluación externa de la calidad de la microscopía, los cultivos, 
las pruebas de sensibilidad a fármacos y los medios de diagnóstico 
molecular. Los sistemas de gestión de la calidad deberían promover 
también el desarrollo de programas de acreditación para garantizar 
Resumen
Contribución de los laboratorios y los sistemas de laboratorio a la eficacia de los programas 
antituberculosos
el cumplimiento de las normas destinadas a mejorar tanto la 
calidad como la credibilidad de los sistemas de laboratorio en 
los programas antituberculosos. Paralelamente hay que prestar 
atención asimismo a los recursos humanos en todos los niveles 
del laboratorio, considerando especialmente los nuevos programas 
respecto de la gestión de laboratorio y las aptitudes de liderazgo. 
El fortalecimiento de las redes de laboratorio exigirá también la 
creación de alianzas entre los programas antituberculosos y los 
que intentan controlar otras enfermedades a fin de mancomunar 
los recursos y de promover la adopción de normas de calidad, 
formular estrategias para integrar las funciones de los laboratorios 
y extender las actividades de los programas de control al sector 
privado. Mejorando los sistemas de laboratorio se logrará que 
se inviertan más recursos, en forma de suministros, equipo e 
instalaciones, en redes capaces de realizar pruebas eficaces con 
miras a alcanzar las metas del Plan Mundial para Detener la 
Tuberculosis.
صخلم
لسلا ةحفاكلم ةلا َّعفلا جمابرلا في اهمُظُنو تابرتخلما راودأ
 هم ِّدقت  الم  ،لسلا  ةحفاكلم  ةيساسلأا  تام ِّوقلما  نم  اهتاكبشو  تابرتخلما  دعُت
 نم  ىوتسم  لك  لىع  ةجلاعلما  ةبقارمو  د ُّصرـتلاو  صيخشتلل  تارابتخا  نم
 ةديدجلا دراولماو تاردابلما نإ .ةيحصلا ةياعرلا مظن تايوتسم نم تايوتسم
 ،لسلا فشكل ةديدجلاو ةعيسرلا تارابتخلاا ذيفنتو تابرتخلما تاردق زيزعتل
 ةيشربلا دراولماو ةدوجلا يرـياعلم جاتحت ٌمُظُن تابرتخلما نأب فارـتعلاا بَّلطتت
 تاكبش  ةئيهت  لجأ  نمو  .تادادملإاو  تادعمللو  ةملاسلل  هابتنلااو  ةئملالما
 اهيف  تاردُقلا  عيسوتلو  ةديدجلا  ةيصيخشتلا  داولما  عم  لماعتلل  تابرتخلما
 يرفوت للاخ نم كلذو ،ةدوجلا ةرادإ مُظُن ةيوقت لىع دوهجلا زيكرـت نم دبلا
 رابتخاو  ،يرهجلما  صحفلا  ةدوج ميـيقتل  ةيجراخلا  جمابرلل  ةيفاضلإا  دراولما
 نأ ةدوجلا ةرادإ مُظُنل دبلاو ،ةيئيزجلا ةيصيخشتلا داولماو ةيودلأل ةباجتسلاا
 ةدوجلا نم ٍّلك ينسحتل يرـياعلماب مازـتللاا نماضل دماتعلاا جمارب ريوطت ززعت
 ءلايإ نم ًاضيأ دبلاو .لسلا ةحفاكم جمارب نمض تابرتخلما ماظنل ةيقوثولماو
 ،تابرتخلما  تايوتسم  نم  ىوتسم  لك  لىع  ةيشربلا  دراولما  ةيبلتل  مماتهلاا
 .ةدايقلا  تاراهمو تابرتخلما ةرادلإ ةديدجلا جمابرلل صاخ مماتها ءلايإ عم
 ةحفاكم جمارب ينب تاكاشرلا دادعإ لىع تابرتخلما تاكبش ةيوقت لمتشتسو
 زيزعتو دراولما عيمجت لجأ نم كلذو ،ىرخلأا ضارملأا ةحفاكم جماربو لسلا
 لماكتلل  تايجيتارـتسلاا  عضولو  ،ةدوجلا  يرـياعم  دادعلإ ةيملاعلإا  تلامحلا
 .صاخلا عاطقلا لىإ لسلا ةحفاكم ةطشنأ قاطن دلمو ،تابرتخلما فئاظو ينب
 تادادمإ  لكشب  ،دراولما  في  ةدايزلا  نأ  نمضيس تابرتخلما  مُظُن  ينسحت  نإ
 اهنكيم  ىتح  تابرتخلما  تاكبش  في  تارماثتسا  نوكتس  ،قفارمو  تادعمو
.لسلا رحدل ةيلماعلا ةطخلل يمارلما قيقحتل ةلا َّعف تارابتخا ميدقت
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